Print Email this page In the News

Pryor Cashman partners Stephen Goodman and Larry Remmel represented Nastech Pharmaceutical Company (Nasdaq: NSTK) in connection with its entering into an agreement on June 26, 2006 with Amylin Pharmaceuticals to develop a nasal spray formulation of exenatide. Under the agreement, Nastech will receive milestone payments and royalties on product sales. If the program moves forward, milestone payments could reach up to $89 million, based on specific development, regulatory and commercialization goals. If a supply agreement is reached between the companies, Nastech may supply commercial product to Amylin and its exenatide collaboration partner, Eli Lilly & Co.